TEVA · Teva Pharmaceutical Industries
AI read · Good for TEVA
The AI's read
Oppenheimer's higher estimate suggests it sees more room for Teva's shares. But this is one firm's view, not new information about Teva's sales, profits, or drug demand.
Oppenheimer increased its price target for Teva Pharmaceutical Industries from $52 to $54.
Good for TEVA
Oppenheimer raised its target for Teva's shares from $52 to $54 and kept its Outperform rating. This is a more positive analyst view, but it reports no change in Teva's business.
Get alerts for TEVA
Follow Teva Pharmaceutical Industries (TEVA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TEVAFree on the App Store and Google Play, or on the web.